adtralza
leo pharma a/s - tralokinumab - dermatiit, atoopiline - muud dermatoloogilised preparaadid - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
bimzelx
ucb pharma s.a. - bimekizumab - psoriaas - immunosupressandid - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
sotyktu
bristol-myers squibb pharma eeig - deucravacitinib - psoriaas - immunosupressandid - treatment of moderate-to-severe plaque psoriasis in adults.
ebglyss
almirall, s.a. - lebrikizumab - dermatiit, atoopiline - muud dermatoloogilised preparaadid - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
celvapan
nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vaktsiinid - a (h1n1) v 2009 viirusega põhjustatud gripi profülaktika. celvapan tuleks kasutada vastavalt euroopa liidu arendus.
ceprotin
takeda manufacturing austria ag - inimese valk c - purpura fulminans; protein c deficiency - antitrombootilised ained - ceprotin is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.
hexyon
sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaktsiinid - hexyon (dtap-ipv-hb-hib) on näidustatud esmaseks ning imikutele ja väikelastele alates kuue nädala vanused difteeria, teetanuse, läkaköha, b-hepatiidi, poliomüeliidi ja haemophilus influenzae tüüp b (hib) poolt põhjustatud invasiivse haiguse vastu. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.
vaxelis
mcm vaccine b.v. - difteeria toxoid, teetanus toxoid, bordetella pertussis ' e antigeenid: läkaköha toxoid, filamentous hemaglutiniini pertactin, fimbriae tüübid 2 ja 3, b-hepatiidi pinna antigeeni toodetud pärmseente rakud, poliovirus (inaktiveeritud): tüüp 1 (mahoney), tüüp 2 (mef-1), tüüp 3 (saukett) toodetud vero rakkudel/ haemophilus influenzae tüüp b polüsahhariid (polyribosylribitol fosfaat), mis on konjugeeritud meningokoki-valk. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vaktsiinid - vaxelis (dtap-hb-ipv-hib) on näidustatud esmaseks ning imikutele ja väikelastele alates 6 nädala vanusest difteeria, teetanuse, läkaköha, b-hepatiidi, poliomüeliidi ja haemophilus influenzae tüüp b (hib) poolt põhjustatud invasiivse haiguse vastu. vaxeli kasutamine peab toimuma kooskõlas ametlike soovitustega.
hemlibra
roche registration limited - emicizumab - hemofiilia a. - antihemorraagilised ained - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra saab kasutada kõigis vanuserühmades.
niontix meditsiiniline vedelgaas
linde sverige ab - dilämmastikoksiid - meditsiiniline vedelgaas - 100% 50l 9tk